Overview Dividends

(HRTX) Heron Therapeuti - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4277461020

Chemotherapy-Nausea Drug, Post-Surgery-Nausea Drug, Extended-Release-Gel

Biotechnology
Market Cap in USD: 235m
IPO / Inception: 1987-08-26
Return 12m vs S&P 500: -27.8%

EPS (Earnings per Share)

EPS (Earnings per Share) of HRTX over the last years for every Quarter: "2020-12": -0.68, "2021-03": -0.58, "2021-06": -0.62, "2021-09": -0.51, "2021-12": -0.54, "2022-03": -0.63, "2022-06": -0.55, "2022-09": -0.38, "2022-12": -0.17, "2023-03": -0.27, "2023-06": -0.35, "2023-09": -0.17, "2023-12": -0.07, "2024-03": -0.02, "2024-06": -0.06, "2024-09": -0.0317, "2024-12": 0.02, "2025-03": 0.0134, "2025-06": -0.02, "2025-09": -0.0361,
EPS CAGR: 60.82%
EPS Trend: 90.2%
Last SUE: -0.52
Qual. Beats: 0

Revenue

Revenue of HRTX over the last years for every Quarter: 2020-12: 20.605, 2021-03: 20.018, 2021-06: 22.443, 2021-09: 23.23, 2021-12: 20.655, 2022-03: 23.457, 2022-06: 27.63, 2022-09: 26.557, 2022-12: 30.028, 2023-03: 29.615, 2023-06: 31.762, 2023-09: 31.434, 2023-12: 34.233, 2024-03: 34.67, 2024-06: 36.024, 2024-09: 32.81, 2024-12: 40.781, 2025-03: 38.903, 2025-06: 37.2, 2025-09: 38.213,
Rev. CAGR: 17.83%
Rev. Trend: 91.8%
Last SUE: -0.32
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 85.1%
Value at Risk 5%th 113%
Relative Tail Risk -19.46%
Reward TTM
Sharpe Ratio 0.09
Alpha -31.10
CAGR/Max DD -0.24
Character TTM
Hurst Exponent 0.487
Beta 0.916
Beta Downside 0.604
Drawdowns 3y
Max DD 83.38%
Mean DD 45.43%
Median DD 50.15%

Description: HRTX Heron Therapeuti December 31, 2025

Heron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotech that leverages its proprietary Biochronomer delivery platform to extend the exposure of short-acting drugs, enabling single-dose regimens that last from days to weeks. Its current marketed products include SUSTOL (granisetron) for chemotherapy-induced nausea and vomiting (CINV) in moderate-risk regimens and CINVANTI (IV aprepitant) for high- and moderate-risk CINV, while its pipeline features ZYNRELEF (bupivacaine/meloxicam) for postoperative pain and APONVIE (IV NK-1 antagonist) for postoperative nausea and vomiting.

Key quantitative signals as of Q3 2024: market capitalization ≈ $210 M; cash and equivalents $95 M, giving roughly 12-month runway at current burn (~$8 M / quarter). The CINV market is projected to grow > 6% CAGR through 2028, driven by increasing oncology therapy utilization and stronger reimbursement for antiemetic combos. Heron’s recent FDA approval of CINVANTI’s expanded indication (2023) lifted its revenue run-rate to $12 M (FY 2023) and the company expects ZYNRELEF to add $15-$20 M in annual sales if it secures a 2025 launch.

For a deeper quantitative view, you might explore ValueRay’s analyst dashboard.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-13.6m TTM) > 0 and > 6% of Revenue (6% = 9.31m TTM)
FCFTA -0.13 (>2.0%) and ΔFCFTA -8.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 90.07% (prev 79.60%; Δ 10.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.12 (>3.0%) and CFO -30.2m <= Net Income -13.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (170.3m) change vs 12m ago 11.46% (target <= -2.0% for YES)
Gross Margin 71.68% (prev 72.19%; Δ -0.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 66.04% (prev 62.39%; Δ 3.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -0.59 (EBITDA TTM -2.57m / Interest Expense TTM 8.33m) >= 6 (WARN >= 3)

Altman Z'' -30.50

(A) 0.56 = (Total Current Assets 229.4m - Total Current Liabilities 89.7m) / Total Assets 248.9m
(B) -7.78 = Retained Earnings (Balance) -1.94b / Total Assets 248.9m
warn (B) unusual magnitude: -7.78 — check mapping/units
(C) -0.02 = EBIT TTM -4.92m / Avg Total Assets 234.9m
(D) -8.27 = Book Value of Equity -1.94b / Total Liabilities 234.1m
Total Rating: -30.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 31.57

1. Piotroski 1.50pt
2. FCF Yield -9.74%
3. FCF Margin -20.08%
4. Debt/Equity 9.44
5. Debt/Ebitda -37.93
6. ROIC - WACC (= -9.16)%
7. RoE 72.92%
8. Rev. Trend 91.78%
9. EPS Trend 90.19%

What is the price of HRTX shares?

As of January 01, 2026, the stock is trading at USD 1.30 with a total of 1,173,816 shares traded.
Over the past week, the price has changed by +1.56%, over one month by +13.04%, over three months by +3.17% and over the past year by -15.03%.

Is HRTX a buy, sell or hold?

Heron Therapeuti has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy HRTX.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the HRTX price?

Issuer Target Up/Down from current
Wallstreet Target Price 4.5 246.2%
Analysts Target Price 4.5 246.2%
ValueRay Target Price 1.2 -10.8%

HRTX Fundamental Data Overview December 27, 2025

Market Cap USD = 234.7m (234.7m USD * 1.0 USD.USD)
P/S = 1.5133
P/B = 33.4193
P/EG = -0.18
Beta = 1.343
Revenue TTM = 155.1m USD
EBIT TTM = -4.92m USD
EBITDA TTM = -2.57m USD
Long Term Debt = 139.7m USD (from longTermDebt, last quarter)
Short Term Debt = 780.0k USD (from shortTermDebt, last quarter)
Debt = 140.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 97.4m USD (from netDebt column, last quarter)
Enterprise Value = 319.7m USD (234.7m + Debt 140.4m - CCE 55.5m)
Interest Coverage Ratio = -0.59 (Ebit TTM -4.92m / Interest Expense TTM 8.33m)
FCF Yield = -9.74% (FCF TTM -31.1m / Enterprise Value 319.7m)
FCF Margin = -20.08% (FCF TTM -31.1m / Revenue TTM 155.1m)
Net Margin = -8.75% (Net Income TTM -13.6m / Revenue TTM 155.1m)
Gross Margin = 71.68% ((Revenue TTM 155.1m - Cost of Revenue TTM 43.9m) / Revenue TTM)
Gross Margin QoQ = 59.74% (prev 73.50%)
Tobins Q-Ratio = 1.28 (Enterprise Value 319.7m / Total Assets 248.9m)
Interest Expense / Debt = 2.06% (Interest Expense 2.90m / Debt 140.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -3.89m (EBIT -4.92m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.56 (Total Current Assets 229.4m / Total Current Liabilities 89.7m)
Debt / Equity = 9.44 (Debt 140.4m / totalStockholderEquity, last quarter 14.9m)
Debt / EBITDA = -37.93 (negative EBITDA) (Net Debt 97.4m / EBITDA -2.57m)
Debt / FCF = -3.13 (negative FCF - burning cash) (Net Debt 97.4m / FCF TTM -31.1m)
Total Stockholder Equity = -18.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.45% (Net Income -13.6m / Total Assets 248.9m)
RoE = 72.92% (negative equity) (Net Income TTM -13.6m / Total Stockholder Equity -18.6m)
RoCE = -4.07% (EBIT -4.92m / Capital Employed (Equity -18.6m + L.T.Debt 139.7m))
RoIC = -2.67% (negative operating profit) (NOPAT -3.89m / Invested Capital 145.6m)
WACC = 6.49% (E(234.7m)/V(375.1m) * Re(9.39%) + D(140.4m)/V(375.1m) * Rd(2.06%) * (1-Tc(0.21)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.47%
Fair Price DCF = unknown (Cash Flow -31.1m)
EPS Correlation: 90.19 | EPS CAGR: 60.82% | SUE: -0.52 | # QB: 0
Revenue Correlation: 91.78 | Revenue CAGR: 17.83% | SUE: -0.32 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.05 | Chg30d=-0.075 | Revisions Net=+1 | Growth EPS=+0.0% | Growth Revenue=+11.6%

Additional Sources for HRTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle